NIKKEI 225
26,599.50 +52.45 (+0.20%) HANG SENG
20,232.29 +282.08 (+1.41%) CRUDE OIL
113.96 -0.24 (-0.21%) GOLD FUTURES
1,825.60 +11.60 (+0.64%) DOW
32,223.42 +26.76 (+0.08%) BTC-GBP
24,291.38 -514.24 (-2.07%)
GenSight Biologics S.A. (GSGTF)
- Business Wire
GenSight Biologics: Annual General Meeting on May 25, 2022
PARIS, May 04, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 25, 2022, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France (*).
- Business Wire
GenSight Biologics Announces the Filing of its 2021 Universal Registration Document
PARIS, April 29, 2022--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2021 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.22-0390.
- Business Wire
GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022
PARIS, April 21, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and revenues as of March 31, 2022.
